Key takeaways
- TA698 & TA1000 Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route at the same £20,000–£30,000/QALY threshold
- £60–90M Estimated annual NHS England Highly Specialised Services spend on PNH complement inhibitors across ~600 patients
- TA1000 NICE's 1,000th technology appraisal (4 Sept 2024), recommending iptacopan for the full adult PNH-with-haemolytic-anaemia population, not just IV-intolerant patients
Ravulizumab and iptacopan both cleared NICE's standard Technology Appraisal route at the same £20,000–£30,000/QALY bar; the live access question is how fast NHS converts patients onto oral iptacopan.
Ravulizumab (Ultomiris, AstraZeneca) and predecessor eculizumab were appraised via NICE's standard Technology Appraisal route, the same ordinary pathway used for most branded medicines, at the standard £20,000–£30,000 per QALY threshold. NICE TA698 (19 May 2021) recommended ravulizumab, contingent on a commercial arrangement, for patients with high disease activity or stable disease after at least six months on eculizumab; NHS England Highly Specialised Services now commissions it through 15 designated centres, and a completed switch programme moved an estimated 95% of NHS PNH patients from eculizumab to ravulizumab by 2023. Estimated NHS HSS spend on PNH complement inhibitors runs to £60–90 million a year across roughly 600 patients at post-arrangement net pricing.
Iptacopan (Fabhalta, Novartis) cleared the identical standard Technology Appraisal route: NICE TA1000 (4 September 2024, NICE's 1,000th published appraisal) recommends iptacopan, within its marketing authorisation, for adults with PNH and haemolytic anaemia (a broad population, with no restriction to patients intolerant of IV anti-C5 therapy), contingent on a commercial arrangement. With cost-effectiveness settled at the standard £20,000–£30,000/QALY threshold and a commercial arrangement already agreed, the constraint on iptacopan's UK uptake is no longer appraisal risk but the pace at which NHS complement-inhibitor patients are offered the oral switch from IV ravulizumab, and the commercial-arrangement economics AstraZeneca can defend against an already-entrenched net price.
UK PNH agent NICE and NHS status
| Drug (Brand / INN) | NICE HTA Route | NICE Recommendation & PAS | NHS Commissioning Channel | Cost-Effectiveness Position | Key Payer Risk |
|---|---|---|---|---|---|
| Ultomiris (ravulizumab) | Standard Technology Appraisal (TA698, 19 May 2021) | Recommended with commercial arrangement | NHS England HSS — 15 designated centres | Within standard £20K–£30K/QALY threshold post-arrangement | Iptacopan oral switching, not a negotiated reset, is the pricing risk |
| Fabhalta (iptacopan) | Standard Technology Appraisal (TA1000, 4 Sept 2024) | Recommended with commercial arrangement | NHS England/Wales — mandatory funding live | Within standard £20K–£30K/QALY threshold post-arrangement | Recommended for the full adult PNH-with-haemolytic-anaemia population; no IV-intolerance restriction |
Sources: NICE TA698 Final Appraisal Determination (ravulizumab), 19 May 2021; NICE TA1000 Final Appraisal Determination (iptacopan), 4 September 2024; NHS England Highly Specialised Services PNH commissioning data, 2023.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Now that both ravulizumab and iptacopan have cleared NICE's standard Technology Appraisal route at the same £20,000–£30,000/QALY bar, what commercial-arrangement terms did each secure, and what does that mean for iptacopan's realistic UK net price? • TA698 and TA1000 recommendation terms and commercial-arrangement structure for each drug • standard £20,000–£30,000/QALY threshold benchmarking • net-price positioning implications for iptacopan against ravulizumab's entrenched NHS price
- What is the current NHS England Highly Specialised Services commissioning pathway for PNH complement inhibitors, and how has the eculizumab-to-ravulizumab switch programme changed the patient base? • 15-designated-centre HSS commissioning architecture • switch programme outcomes (~95% of NHS PNH patients now on ravulizumab) • NHS annual spend estimate (£60–90M) and per-patient net cost modelling
- With iptacopan already NICE-recommended (TA1000) for the full PNH-with-haemolytic-anaemia population, how quickly will NHS HSS centres offer the oral switch to patients currently stable on IV ravulizumab? • TA1000 mandatory NHS funding timeline • centre-level readiness for oral complement-inhibitor switching • commercial-arrangement economics shaping AstraZeneca's and Novartis's competing net-price positions
What's inside
-
1 · UK PNH Payer & Commissioning Landscape — NHS England HSS Overview 4 pp
- [object Object]
- [object Object]
-
2 · NICE Standard Technology Appraisal Route — TA698 and TA1000 Compared 6 pp
- [object Object]
- [object Object]
-
3 · NHS PNH Commissioning Cost & the Eculizumab-to-Ravulizumab Switch 5 pp
- [object Object]
- [object Object]
-
4 · Iptacopan NICE TA1000 — Commercial Arrangement & NHS Conversion Timeline 5 pp
- [object Object]
- [object Object]
-
5 · NHS HSS Centre Network — Access Pathway & Oral Conversion Readiness 3 pp
- [object Object]
- [object Object]
-
6 · Devolved Nations — Scotland (SMC) and Wales (AWMSG) Divergence Risk 3 pp
- [object Object]
- [object Object]
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx PNH Payer & HTA is built for market access, HEOR, and pricing teams navigating NICE's standard Technology Appraisal route for both ravulizumab and iptacopan and NHS England HSS commissioning in the UK PNH market. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (NICE HST/TA, NHS commissioning, PAS), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, NICE classification analysis, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from NICE's published Technology Appraisal documentation, NHS England Highly Specialised Services commissioning specifications, and payer-facing evidence submissions for ravulizumab and iptacopan in PNH.
Key sources: NICE TA698 Final Appraisal Determination (ravulizumab), 19 May 2021; NICE TA1000 Final Appraisal Determination (iptacopan), 4 September 2024; NHS England HSS PNH commissioning and resource-use data, 2023. Devolved-nation positions (Scotland's SMC, Wales's AWMSG) are assessed against NICE's Technology Appraisal precedent separately, reflecting their distinct advisory and adoption mechanisms relative to NHS England's mandatory funding obligation.
- NICE Technology Appraisal status for both drugs verified against the published TA698 and TA1000 Final Appraisal Determinations
- NHS England HSS commissioning structure (15 designated centres) and switch-programme outcome (~95% of patients on ravulizumab) verified against NHS England HSS PNH commissioning data, 2023
- Iptacopan cost-effectiveness position verified against the published TA1000 Final Appraisal Determination and standard TA QALY threshold documentation
- Commercial arrangement status for both drugs verified against the published TA698 and TA1000 guidance
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: the NICE appraisals for ravulizumab and iptacopan, NHS England highly specialised service commissioning and resource-use data, and published devolved-nation access positions. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.